GlassScriptPhysician profile
Steven D Stone
NPI 1932480720
$199,895.44
in general payments reported to CMS, 2019-2025
48 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33K · 2022: $28K · 2023: $48K · 2024: $47K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $25K · Consulting Fee: $23K · Food and Beverage: $7,073 · Honoraria: $2,000 · Education: $905 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,808.25 |
| Travel and Lodging | $24,662.06 |
| Consulting Fee | $23,489.50 |
| Food and Beverage | $7,072.57 |
| Honoraria | $2,000.00 |
| Education | $905.21 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $267.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51,298.99 | 2021-2025 | Calquence |
| Glaxosmithkline, LLC. | $39,537.54 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $36,360.53 | 2021-2025 | Kyprolis, Kyprolis |
| Alexion Pharmaceuticals, INC. | $26,029.34 | 2021-2025 | Ultomiris, Voydeya, Soliris |
| Apellis Pharmaceuticals, INC. | $21,906.64 | 2022-2024 | Empaveli, Empaveli |
| Novartis Pharmaceuticals Corporation | $13,340.47 | 2023-2025 | Fabhalta |
| E.R. Squibb & Sons, L.L.C. | $3,595.36 | 2023 | Pomalyst, Abecma, Eliquis |
| Genzyme Corporation | $2,617.11 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $1,437.50 | 2025 | Darzalex |
| Astellas Pharma US INC | $609.12 | 2021-2025 | Padcev, Vyloy, Xospata |
| Celgene Corporation | $580.14 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $422.71 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $304.51 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $187.00 | 2021-2023 | Imbruvica |
| Incyte Corporation | $171.99 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $141.23 | 2022-2025 | Venclexta, Phesgo, Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $140.96 | 2022-2025 | Fruzaqla |
| Janssen Biotech, INC. | $121.62 | 2024-2025 | Talvey, Carvykti, Tecvayli |
| Abbvie INC. | $108.58 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Merck Sharp & Dohme LLC | $83.49 | 2024-2025 | Keytruda, Lynparza |
| Rigel Pharmaceuticals, INC. | $74.32 | 2021 | |
| Seagen INC. | $61.99 | 2023 | |
| Eisai INC. | $51.66 | 2024-2025 | |
| Beone Medicines USA, INC. | $51.65 | 2025 | Brukinsa |
| Beigene USA, INC. | $49.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $45.50 | 2025 | |
| Gilead Sciences, INC. | $42.99 | 2023 | Trodelvy |
| Genmab U.S., INC. | $35.94 | 2025 | Epkinly |
| Agios Pharmaceuticals, INC. | $28.53 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $25.74 | 2025 | Lynozyfic |
| Adc Therapeutics America, INC. | $25.10 | 2024 | |
| Geron Corporation | $24.66 | 2025 | Rytelo |
| Array Biopharma INC | $23.20 | 2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $22.96 | 2025 | Zoladex |
| Taiho Oncology, INC. | $22.19 | 2025 | |
| Pharmaessentia USA Corporation | $20.45 | 2025 | Besremi |
| Progenics Pharmaceuticals, INC. | $20.36 | 2024 | |
| Puma Biotechnology, INC. | $20.21 | 2022 | |
| Global Blood Therapeutics, INC. | $19.72 | 2021 | |
| Caris Mpi, INC. | $19.64 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $18.84 | 2025 | Orserdu |
| Lilly USA, LLC | $18.36 | 2024 | Jaypirca, Retevmo, Verzenio |
| Syndax Pharmaceuticals, INC. | $16.51 | 2025 | |
| Invivyd INC | $16.48 | 2025 | Pemgarda |
| Janssen Pharmaceuticals, INC | $15.46 | 2023 | Xarelto |
| Springworks Therapeutics, INC. | $14.84 | 2024 | Ogsiveo |
| Blueprint Medicines Corporation | $13.86 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.